Most agonist mAbs targeting CD40 are of the IgG1 subclass with different levels of affinity to CD40 and depend on crosslinking with FcγRs in order to facilitate CD40 aggregation for APCs activation (79, 80) as well as an ADCC activity against tumor cells (81, 82) (Table 6). This evidence concerns the gene CD40 and neoplasm.